These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20222913)

  • 21. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
    Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
    Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine in patients with Crohn's disease.
    Markowitz JF
    Rev Gastroenterol Disord; 2003; 3 Suppl 1():S23-9. PubMed ID: 12684586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of pancreatitis by weekly amylase assay in patients with Crohn's disease treated with azathioprine.
    Castiglione F; Del Vecchio Blanco G; Rispo A; Mazzacca G
    Am J Gastroenterol; 2000 Sep; 95(9):2394-5. PubMed ID: 11007256
    [No Abstract]   [Full Text] [Related]  

  • 24. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery.
    Papay P; Reinisch W; Ho E; Gratzer C; Lissner D; Herkner H; Riss S; Dejaco C; Miehsler W; Vogelsang H; Novacek G
    Am J Gastroenterol; 2010 May; 105(5):1158-64. PubMed ID: 20010925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 6-Thioguanine therapy in Crohn's disease--observational data in Swedish patients.
    Almer SH; Hjortswang H; Hindorf U
    Dig Liver Dis; 2009 Mar; 41(3):194-200. PubMed ID: 18799369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Azathioprine and 6-mercaptopurine for Crohn's disease.
    Lancet; 1980 Aug; 2(8189):298-9. PubMed ID: 6105443
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical predictors of thiopurine-related adverse events in Crohn's disease.
    Moran GW; Dubeau MF; Kaplan GG; Yang H; Eksteen B; Ghosh S; Panaccione R
    World J Gastroenterol; 2015 Jul; 21(25):7795-804. PubMed ID: 26167079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute pancreatitis as a complication of Imuran therapy in regional enteritis.
    Nogueira JR; Freedman MA
    Gastroenterology; 1972 May; 62(5):1040-1. PubMed ID: 5029069
    [No Abstract]   [Full Text] [Related]  

  • 29. [Azathioprine, 6-mercaptopurine, and inflammatory diseases of the intestine].
    Beaugerie L; Gendre JP
    Gastroenterol Clin Biol; 1990; 14(3):230-40. PubMed ID: 2188863
    [No Abstract]   [Full Text] [Related]  

  • 30. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
    Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
    Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
    Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
    Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum sickness associated with 6-mercaptopurine in a patient with Crohn's disease.
    Andersen JM; Tiede JJ
    Pharmacotherapy; 1997; 17(1):173-6. PubMed ID: 9017780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease.
    Kim PS; Zlatanic J; Korelitz BI; Gleim GW
    Am J Gastroenterol; 1999 Nov; 94(11):3254-7. PubMed ID: 10566725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Compared azathioprine efficacy in ulcerative colitis and in Crohn's disease].
    Kull E; Beau P
    Gastroenterol Clin Biol; 2002 Apr; 26(4):367-71. PubMed ID: 12070412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunosuppressive drugs in Crohn's disease.
    Kornbluth A; George J; Sachar DB
    Gastroenterologist; 1994 Sep; 2(3):239-46. PubMed ID: 7987622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pancreatitis caused by azathioprine: immuno-allergy?].
    Aissaoui M; Mounedji N; Mathelier-Fusade P; Leynadier F
    Presse Med; 1996 Nov; 25(34):1650. PubMed ID: 8975240
    [No Abstract]   [Full Text] [Related]  

  • 37. Neoplasia of the tongue in a patient with Crohn's disease treated with azathioprine: case report.
    Li AC; Warnakulasuriya S; Thompson RP
    Eur J Gastroenterol Hepatol; 2003 Feb; 15(2):185-7. PubMed ID: 12560764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression.
    Allorge D; Hamdan R; Broly F; Libersa C; Colombel JF
    Gut; 2005 Apr; 54(4):565. PubMed ID: 15753546
    [No Abstract]   [Full Text] [Related]  

  • 39. Summary of the workshop on 6-mercaptopurine/azathioprine pharmacology.
    Markowitz JF
    Inflamm Bowel Dis; 1998 May; 4(2):117-8; discussion 118-20. PubMed ID: 9687220
    [No Abstract]   [Full Text] [Related]  

  • 40. Azathioprine-associated acute pancreatitis.
    Paloyan D; Levin B; Simonowitz D
    Am J Dig Dis; 1977 Sep; 22(9):839-40. PubMed ID: 900102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.